ClinicalTrials.gg
Active, not recruitingNCT05400980Updated Sep 24, 2026

Expander-2 Trial: Randomized Study to Evaluate Safety & Efficacy of the Urocross® Expander System & Retrieval Sheath

An interventional study of Urocross implant and Sham-control in Benign Prostatic Hyperplasia, sponsored by Prodeon Medical, Inc. Active, not recruiting at 2 sites in United States. Open to male participants aged 45 Years and older. Per ClinicalTrials.gov, last updated 2026-09-24.

Sponsored by Prodeon Medical, Inc · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
45 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 188 studies in Prostatic Hyperplasia with a site in United States — 29 open to participants now, 48 under way, none of them phase 3. Prostatic Hyperplasia · United States.

Planned enrollment
36th of 150
240 · median 83
Started
2022
with 9 others
No phase
63 of 188
13 open now
Primary completion
2027-01
later than 17 of 47 live
Registered
148th of 188
by date

Among the 188 studies in Prostatic Hyperplasia with a site in United States, this one is the 36th largest by planned enrollment of the 150 interventional ones that give a count, is one of 10 that started in 2022, is one of 63 with no phase, reaches primary completion later than 17 of the 47 other live ones, and was the 148th registered.

Prostatic Hyperplasia

831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

29 of the 188 studies in Prostatic Hyperplasia with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Prostatic Hyperplasia with a site in United States, or all of them as a file.
02

Study summary

To demonstrate the safety and efficacy of the Urocross Expander System/Retrieval Sheath and the procedure to treat patients with symptomatic Benign Prostatic Hyperplasia (BPH).

Read the detailed description

Pivotal, prospective, multi-center, randomized, sham-controlled, blinded study

03

Conditions studied

  • Benign Prostatic Hyperplasia

Browse trials for

Keywords

  • Prostate
  • BPH
  • Benign
  • Minimally Invasive
  • Temporary
04

Who can participate

Ages eligible
45 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subject has signed an form (ICF).
  2. Men ≥ 45 years.
  3. Symptomatic BPH with the following (all must be met):

    • IPSS ≥ 13.
    • Qmax ≤ 12 mL/sec on a voided volume of ≥ 125 mL.
    • PVR \< 250 mL.
  4. Prostate volume 30-80 cc measured by transrectal ultrasound (TRUS) or magnetic resonance imaging (MRI) within 6 months prior to randomization.
  5. Subjects willing to be off their BPH-related medications from time of enrollment and throughout study participation.

Note: All subjects on BPH-related medications must start a prior to qualifying questionnaires and uroflowmetry.

Exclusion criteria

Exclusion Criteria:

Subjects who meet ANY of the following exclusion criteria will not participate in the trial:

  1. Previous BPH procedure intended to disobstruct the bladder outlet (e.g., prostate surgery, stent implantations, laser prostatectomy, hyperthermia or another invasive treatment to the prostate).
  2. Obstructive protruding (mobile) middle (median) prostatic lobe as confirmed by cystoscopy.
  3. High bladder neck as determined by the Investigator.
  4. Urethral stricture, meatal stenosis, or bladder neck contraction - either current, or recurrent requiring 2 or more dilatations.
  5. of the prostate within past 8 weeks.
  6. Baseline Prostate Specific Antigen (PSA) level > 10 ng/mL or confirmed or suspected prostate cancer (subjects with a PSA level > 2.5 ng/mL or whose PSA levels fall outside age-specific or local reference ranges, should have prostate cancer excluded to the Investigator's satisfaction in conjunction with shared decision making [SDM] with the study subjects).
  7. Confirmed or suspected bladder cancer.
  8. History of cystolithiasis, kidney stone, or kidney disease within the prior 3 months.
  9. History of neurogenic bladder.
  10. Previous episode of AUR, i.e., post hernia repair or other condition or disease that might cause urinary retention.
  11. Parkinson's disease or other neurologic disease known to impact bladder function (e.g., stroke, , multiple sclerosis).
  12. Serum creatinine > 1.8 mg/dL or renal dysfunction attributed to bladder outlet obstruction (BOO).
  13. Concomitant UTI (subject can be enrolled following successful treatment of UTI and a negative UTI test), or subjects who have a history of recurrent or chronic UTIs (defined as 2 or more UTIs in the past 12 months).
  14. Active infection including acute bacterial prostatitis.
  15. Previous pelvic irradiation or radical pelvic surgery.
  16. Known allergy to nickel.
  17. Subjects with life-threatening disease in which is foreshortened are excluded.
  18. Desire to maintain fertility post-treatment.
  19. Anticipated need for additional major surgery or treatments for comorbidities during the study period (e.g., valve repair, organ transplant).
  20. Prostatic urethral length \< 25 mm or > 60 mm, as measured from bladder neck to verumontanum, using cystoscopy just prior to randomization.
  21. Any concurrent medical condition or illness that might prevent study completion or that could impact the study results such as:

    • severe cardiac arrhythmias uncontrolled by medications or pacemaker.
    • congestive heart failure (NYHA) III or IV.
    • uncontrolled diabetes mellitus.
    • significant respiratory disease in which hospitalization may be required.
    • known (i.e., AIDS, post-transplant, undergoing chemotherapy).
  22. Inability to stop taking anticoagulants and/or antiplatelets for at least 3 days prior to the procedure or coumadin for at least 5 days prior to the procedure.

    Note: Low dose aspirin therapy is acceptable.

  23. Unable or unwilling to complete all required questionnaires and follow-up assessments.
  24. Participating in any other study for either drug or device which can influence collection of valid data under this study.
  25. Subject is in custody or institution, or, in the Investigator's opinion, has a physical, psychological, or medical impairment that might prevent study completion or would confound study results (including subject questionnaires).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Urocross implant group

    The investigational products in this trial are the Urocross Expander Implant as delivered by the Urocross Expander System and the Urocross Retrieval Sheath used to retrieve the implant after 6 months following its implant.

    Device: Urocross implant

  • Sham comparator
    Sham-control group

    The sham-control in this trial is cystoscopy only.

    Diagnostic Test: Sham-control

Interventions

  • DeviceUrocross implant

    Urocross implant inserted via delivery catheter

  • Diagnostic testSham-control

    Cystoscopy

06

What researchers measure

Primary outcomes

  1. Safety of Urocross Expander Implant

    The rate of extended post-operative urinary catheterization (more than 7 days) from treatment for inability to void.

    Time frame: more than 7 days post procedure

  2. Efficacy of the Urocross Expander Implant as delivered by the Urocross Expander System and the Urocross Retrieval Sheath

    The primary efficacy endpoint is Change from Baseline in Total International Prostate Symptom Score (IPSS) at 3 months post-procedure. The IPSS items range in score from 0-5, with higher scores indicating worse symptoms. The study is powered to show that the average improvement in Total IPSS among the Urocross Implant subjects is more than 25% greater than the average improvement in Total IPSS among the sham-control subjects.

    Time frame: 3 months post-procedure

Secondary outcomes

  1. Percent change in Total IPSS for subjects randomized to the Urocross Implant

    The major secondary efficacy endpoint is the percent change in Total IPSS from baseline (i.e., pre-procedure) to 3 months post-procedure for subjects randomized to the Urocross Implant group. The IPSS items range in score from 0-5, with higher scores indicating worse symptoms.

    Time frame: 3 months post-procedure

07

Study locations

2 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2022 (actual). Primary completion is estimated for Jan 2027, 54 months after the start.

Of 52 industry-sponsored interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 50. This study's planned 54 months is above that.

Counting every sponsor, half of 207 studies reached it within 27 months; a quarter within 15 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2022
First posted
Jun 2, 2022
StartActual
Jul 5, 2022
Primary completionEst.
Jan 2027
CompletionEst.
Dec 2028
Last update
Sep 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05400980
Lead sponsor
Prodeon Medical, Inc
Responsible party
Sponsor
First posted
Jun 2, 2022
Start date
Jul 5, 2022
Primary completion
Jan 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 24, 2026

Study contacts

Kevin T. McVary
principal investigator · Loyola University
Daniel B. Rukstalis
principal investigator · Carilion Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion